首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
医学
The American Society of Clinical Oncology wrapped its annual conference this week, going through the usual motions of presenting
The American Society of Clinical Oncology wrapped its annual conference this week, going through the usual motions of presenting
admin
2018-02-26
15
问题
The American Society of Clinical Oncology wrapped its annual conference this week, going through the usual motions of presenting a lot of drugs that offer some added quality or extension of life to those suffering from a variety of as-yet incurable diseases. But buried deep in an AP story are a couple of promising headlines that seems worthy of more thorough review, including one treatment study where 100 percent of patients saw their cancer diminish by half.
First of all, it seems pharmaceutical companies are moving away from the more cost-effective one-size-fits-all approach to drug development and embracing the long tail of cancer treatments, engineering drugs that only work for a small percentage of patients but work very effectively within that group.
Pfizer announced that one such drug it’s pushing into late-stage testing is target for 4% of lung cancer patients. But more than 90% of that tiny cohort responded to the drug in initial tests, and nine out often is getting pretty close to the ideal ten out of ten. By gearing drugs toward more boutique treatments rather than broad umbrella pharmaceuticals that try to fit for everyone it seems cancer researchers are making some headway. But how can we close the gap on that remaining ten percent?
Ask Takeda Pharmaceutical and Celgene, two drug makers who put aside competitive interests to test a novel combination of their treatments. In a test of 66 patients with the blood disease multiple myeloma, a full 100 percent of the subjects saw their cancer reduced by half. Needless to say, a 100 percent response to a cancer drug (or in this case a drug cocktail) is more or less unheard of. Moreover, this combination never would’ve been tried if two competing companies hadn’t sat down and put their heads together.
Are there more potentially effective drug combos out there separated by walls of competitive interest and proprietary information? Who’s to say, but it seems like with the vast amount of money and research being pumped into cancer drug development, the odds are pretty good. And if researchers can start pushing more of their response numbers toward 100 percent, we can more easily start talking about oncology’s favorite four-letter word: cure.
The tone of the author of this passage seems to be______.
选项
A、neutral
B、critical
C、negative
D、optimistic
答案
D
解析
细节题。题意:本文作者的语气是______。从末段最后一句可知,如果研究人员开始把药物效率向百分之百推进,那我们也能更加容易地开始探讨肿瘤界最令人神往的一个词:治愈。即作者很乐观,充满了希望。故本题答案为D。
转载请注明原文地址:https://jikaoti.com/ti/IIxDFFFM
本试题收录于:
医学博士外语题库考研分类
0
医学博士外语
考研
相关试题推荐
Throughlivetelevision,theworldisnowabletowitnesshistoricaleventsastheyhappen.
A、Psychosocialeffectsofbreastsurgery.B、Lifecrisesofcancerpatients.C、Femaleself-imageinsociety.D、Awoman’spercept
Inasocietywhereallaspectsofourlivesaredictatedbyscientificadvancesintechnology,scienceistheessenceofourexi
Inasocietywhereallaspectsofourlivesaredictatedbyscientificadvancesintechnology,scienceistheessenceofourexi
OneofthemostnoticeablefeaturesofU.S.societyisthediversityofitspeople.
ThenorthAmericanstatesagreedtosigntheagreementofeconomicalandmilitaryunioninOttawa.
随机试题
I’mthinkingofgoingtothematchonSaturday.So______.
A.胸腺B.肾上腺C.腺垂体D.甲状腺E.腮腺分泌糖皮质激素的腺体
下列哪一种不属于胃食管反流病的临床表现
患者,男性。38岁。腰部疼痛,重着而热,暑湿阴雨天气症状加重,身体困重,舌苔黄腻,脉濡数或弦数,其治法为
左旋多巴抗帕金森病的机制是
下列哪些情形属于想象竞合犯?
图15—2—4所示静定三铰拱,拉杆AB的轴力等于()。[2013年真题]
案例2005年12月7日15时14分,某煤矿发生一起特别重大瓦斯煤尘爆炸事故,造成108人死亡、29人受伤,直接经济损失4870.67万元。事故发生后,井下未探查区域有害气体严重超标、有爆炸危险,在下落不明矿工无生还可能的特殊情况下,抢
某小朋友在语言活动中,认真地、完整地听完了老师讲的故事。这说明该小朋友具有()。
There’snothingWrongWithMybike.There________________wrongWithMybike.
最新回复
(
0
)